BioCentury
ARTICLE | Company News

Summit, University of Oxford deal

December 9, 2013 8:00 AM UTC

Summit and the university partnered to develop treatments for Duchenne muscular dystrophy (DMD). Under the deal, Summit will acquire MuOx Ltd., an Oxford spinout that houses exclusive rights to utroph...